{"id":31894,"date":"2025-04-16T11:47:48","date_gmt":"2025-04-16T03:47:48","guid":{"rendered":"https:\/\/flcube.com\/?p=31894"},"modified":"2025-04-16T11:47:49","modified_gmt":"2025-04-16T03:47:49","slug":"sichuan-biokin-secures-four-phase-ii-approvals-for-bl-b01d1-in-combination-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31894","title":{"rendered":"Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies"},"content":{"rendered":"\n

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506<\/a>) has announced that it has secured four Phase II clinical trial approvals from the National Medical Products Administration (NMPA) for its in-house developed bispecific antibody drug conjugate (ADC) BL-B01D1. The approvals allow the drug to be tested in combination with other therapies, expanding its potential applications across various tumor types.<\/p>\n\n\n\n

BL-B01D1: First-in-Class Innovation<\/strong>
BL-B01D1 is the only first-in-class ADC targeting EGFR\/HER3 that has reached Phase III clinical trials. It is currently subject to over 30 clinical studies across more than 10 tumor types in both China and the United States. This extensive clinical development underscores Biokin\u2019s commitment to advancing innovative therapies for cancer patients.<\/p>\n\n\n\n

Clinical Development and Future Outlook<\/strong>
The four new Phase II approvals further solidify Biokin\u2019s position in the ADC market, enabling the company to explore BL-B01D1\u2019s efficacy and safety in combination with other drugs. This strategic approach aims to enhance treatment outcomes for patients with diverse tumor types, including those with limited therapeutic options.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has secured four…<\/p>\n","protected":false},"author":1,"featured_media":31895,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,151,16,62,857],"class_list":["post-31894","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-biokin-pharmaceutical","tag-cancer","tag-clinical-trial-approval-initiation","tag-sha-688506"],"yoast_head":"\nSichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has secured four Phase II clinical trial approvals from the National Medical Products Administration (NMPA) for its in-house developed bispecific antibody drug conjugate (ADC) BL-B01D1. The approvals allow the drug to be tested in combination with other therapies, expanding its potential applications across various tumor types.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31894\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies\" \/>\n<meta property=\"og:description\" content=\"China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has secured four Phase II clinical trial approvals from the National Medical Products Administration (NMPA) for its in-house developed bispecific antibody drug conjugate (ADC) BL-B01D1. The approvals allow the drug to be tested in combination with other therapies, expanding its potential applications across various tumor types.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31894\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-16T03:47:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-16T03:47:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1604.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31894#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31894\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies\",\"datePublished\":\"2025-04-16T03:47:48+00:00\",\"dateModified\":\"2025-04-16T03:47:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31894\"},\"wordCount\":187,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31894#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1604.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Biokin Pharmaceutical\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"SHA: 688506\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31894#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31894\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31894\",\"name\":\"Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31894#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31894#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1604.webp\",\"datePublished\":\"2025-04-16T03:47:48+00:00\",\"dateModified\":\"2025-04-16T03:47:49+00:00\",\"description\":\"China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has secured four Phase II clinical trial approvals from the National Medical Products Administration (NMPA) for its in-house developed bispecific antibody drug conjugate (ADC) BL-B01D1. The approvals allow the drug to be tested in combination with other therapies, expanding its potential applications across various tumor types.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31894#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31894\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31894#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1604.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1604.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31894#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies - Insight, China's Pharmaceutical Industry","description":"China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has secured four Phase II clinical trial approvals from the National Medical Products Administration (NMPA) for its in-house developed bispecific antibody drug conjugate (ADC) BL-B01D1. The approvals allow the drug to be tested in combination with other therapies, expanding its potential applications across various tumor types.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31894","og_locale":"en_US","og_type":"article","og_title":"Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies","og_description":"China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has secured four Phase II clinical trial approvals from the National Medical Products Administration (NMPA) for its in-house developed bispecific antibody drug conjugate (ADC) BL-B01D1. The approvals allow the drug to be tested in combination with other therapies, expanding its potential applications across various tumor types.","og_url":"https:\/\/flcube.com\/?p=31894","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-16T03:47:48+00:00","article_modified_time":"2025-04-16T03:47:49+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1604.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31894#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31894"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies","datePublished":"2025-04-16T03:47:48+00:00","dateModified":"2025-04-16T03:47:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31894"},"wordCount":187,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31894#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1604.webp","keywords":["ADC \/ XDC","Biokin Pharmaceutical","Cancer","Clinical trial approval \/ initiation","SHA: 688506"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31894#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31894","url":"https:\/\/flcube.com\/?p=31894","name":"Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31894#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31894#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1604.webp","datePublished":"2025-04-16T03:47:48+00:00","dateModified":"2025-04-16T03:47:49+00:00","description":"China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has secured four Phase II clinical trial approvals from the National Medical Products Administration (NMPA) for its in-house developed bispecific antibody drug conjugate (ADC) BL-B01D1. The approvals allow the drug to be tested in combination with other therapies, expanding its potential applications across various tumor types.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31894#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31894"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31894#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1604.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1604.webp","width":1080,"height":608,"caption":"Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31894#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1604.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31894"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31894\/revisions"}],"predecessor-version":[{"id":31896,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31894\/revisions\/31896"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31895"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}